Drug interactions with newer antidepressants:
role of human cytochromes P450
by
Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI
Department of Pharmacology and Experimental Therapeutics,
Tufts University School of Medicine and New England Medical Center,
Boston, Mass 02111, USA.
Dgreenblatt@Infonet.tufts.edu
J Clin Psychiatry 1998; 59 Suppl 15:19-27

ABSTRACT

Selective serotonin reuptake inhibitors and related antidepressant compounds have the secondary pharmacologic property of inhibiting the activity of human cytochrome P450 enzymes responsible for the oxidative metabolism of many drugs. A number of clinically important pharmacokinetic drug interactions are a consequence of these cytochrome inhibiting effects. This review evaluates the clinical implications of the metabolic profiles of the newer antidepressants, the relative activities of various new antidepressants as inhibitors of human cytochrome P450, and the various in vivo and in vitro methodologies that can be used for identification and quantification of drug interactions.

TCAs
SSRIs
RIMAs
Options
Bupropion
Fluoxetine
Milnacipran
Reboxetine
Nefazodone
Mirtazapine
Venlafaxine
Moclobemide
Antidepressants
Antidepressants: metabolism
Antidepressants and liver injury

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family